
|Articles|April 19, 2004
New antidepressant offers substantial savings
Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Pneumococcal Vaccination at 50 Years Old Can Improve Outcomes
5





























































